ArticleScientific reports2025
Assessment of T-cell subsets and procalcitonin for diagnosing and stratifying severity in community acquired pneumonia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate risk stratification in community-acquired pneumonia (CAP) is essential for guiding timely and effective clinical management. This study evaluated whether the combined assessment of circulating T-lymphocyte subsets (T-cell subsets) and serum procalcitonin (PCT) enhances diagnostic accuracy and severity classification in CAP. T-cell subsets, as markers of immune response, may complement traditional inflammatory biomarkers. A retrospective analysis was conducted on 320 adult CAP patients admitted to a tertiary hospital in Zhejiang, China, between February 2020 and November 2021. Patients were stratified using the Clinical Pulmonary Infection Score (CPIS ≤ 6 vs. > 6) and platelet-to-lymphocyte ratio (PLR ≤ 163 vs. > 163). Laboratory assessments included serum PCT, white blood cell count (WBC), C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), interleukin-6 (IL-6), and T-cell subsets (CD3⁺, CD4⁺, CD8⁺ counts, and CD4/CD8 ratio). Pathogens were identified from 79 positive sputum or blood cultures. Patients with CPIS > 6 had significantly higher levels of PCT, PLR, WBC, CRP, NLR, and IL-6, along with lower CD3⁺ and CD4⁺ T-cell counts, a reduced CD4/CD8 ratio, and elevated CD8⁺ counts (all P < 0.05). Similar trends were observed in patients with PLR > 163. Acinetobacter baumannii was significantly more prevalent in patients classified as moderate-to-high risk or non-survivors (P < 0.05). T-cell subsets monitoring demonstrated a sensitivity of 93.2%, while PCT showed a specificity of 95.6% for predicting CAP severity. Combined evaluation of T-lymphocyte subsets and serum procalcitonin levels enhances the accuracy of CAP severity stratification. The elevated prevalence of Acinetobacter baumannii in severe cases highlights the importance of host-pathogen interactions. Integrated immune and inflammatory profiling may facilitate precision-based management strategies in CAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.